Burkhard-Meier, Anton and Grube, Matthias and Jurinovic, Vindi and Agaimy, Abbas and Albertsmeier, Markus and Berclaz, Luc M. and Di Gioia, Dorit and Duerr, Hans Roland and von Eisenhart-Rothe, Ruediger and Eze, Chukwuka and Fechner, Katja and Fey, Emma and Gueler, Sinan E. and Hecker, Judith S. and Hendricks, Anne and Keil, Felix and Klein, Alexander and Knebel, Carolin and Kovacs, Julia R. and Kunz, Wolfgang G. and Lenze, Ulrich and Loersch, Alisa M. and Lutz, Mathias and Meidenbauer, Norbert and Mogler, Carolin and Schmid, Sebastian and Schmidt-Hegemann, Nina-Sophie and Schneider, Christian and Semrau, Sabine and Sienel, Wulf and Trepel, Martin and Waldschmidt, Johannes and Wiegering, Armin and Lindner, Lars H. (2025) Does Size Outweigh Number in Predicting Survival After Pulmonary Metastasectomy for Soft Tissue Sarcoma? Insights from a Retrospective Multicenter Study. ANNALS OF SURGICAL ONCOLOGY, 32 (8). pp. 5948-5956. ISSN 1068-9265, 1534-4681
Full text not available from this repository. (Request a copy)Abstract
Background. Pulmonary metastasectomy (PM) is the most frequently performed local ablative therapy for leiomyosarcoma (LMS), synovial sarcoma (SyS), and undifferentiated pleomorphic sarcoma (UPS). This study aimed to assess surgical feasibility, outcome, and clinical prognostic factors, as well as the value of a peri-interventional systemic therapy. Methods. This multicenter retrospective study enrolled 77 patients with LMS, SyS, or UPS who underwent first-time complete resection of isolated lung metastases between 2009 and 2021. Disease-free survival (DFS), overall survival (OS), and clinical prognostic factors were analyzed. Results. After the first PM, the median DFS was 7.4 months, and the median OS was 58.7 months. A maximal lesion diameter greater than 2 cm was associated with reduced DFS in both the univariable (hazard ratio [HR], 2.29; p = 0.006) and multivariable (HR, 2.60; p = 0.005) analyses. The univariable analysis identified a maximal lesion diameter greater than 2 cm as an adverse prognostic factor for OS (HR, 5.6; p < 0.001), whereas a treatment-free interval longer than 12 months was associated with improved OS (HR, 0.42; p = 0.032). The addition of systemic therapy was associated with a trend toward improved DFS for patients with lesions larger than 2 cm (HR, 0.29; p = 0.063). Severe postoperative complications (grade >= IIIa) occurred in 2 % of the patients. Conclusion. The size of resected lung metastases might be a more relevant prognostic factor than their number for patients with LMS, SyS, or UPS. For patients with lung metastases larger than 2 cm in maximal diameter, additional systemic therapy may be warranted.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | STEREOTACTIC BODY RADIOTHERAPY; EUROPEAN ORGANIZATION; PROGNOSTIC-FACTORS; CHEMOTHERAPY; Soft tissue sarcoma; Metastasis; Pulmonary metastasectomy; Systemic therapy; Leiomyosarcoma; Synovial sarcoma; Undifferentiated pleomorphic sarcoma |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) Medicine > Lehrstuhl für Pathologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 23 Apr 2026 11:44 |
| Last Modified: | 23 Apr 2026 11:44 |
| URI: | https://pred.uni-regensburg.de/id/eprint/67560 |
Actions (login required)
 |
View Item |
